Bio-Path (NASDAQ:BPTH) Posts Earnings Results, Misses Estimates By $0.27 EPS

Bio-Path (NASDAQ:BPTH) posted its earnings results on Thursday. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.27), reports.

NASDAQ BPTH traded up $0.13 during trading hours on Friday, reaching $12.31. The company’s stock had a trading volume of 129,441 shares, compared to its average volume of 116,461. The firm has a fifty day simple moving average of $13.32 and a 200-day simple moving average of $14.04. The stock has a market cap of $34.17 million, a P/E ratio of -0.86 and a beta of 3.16. Bio-Path has a 52 week low of $1.61 and a 52 week high of $73.52.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Gainplan LLC bought a new position in Bio-Path in the 1st quarter valued at approximately $204,000. Morgan Stanley raised its holdings in Bio-Path by 19,858.0% in the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after buying an additional 19,858 shares during the last quarter. Virtu Financial LLC acquired a new stake in Bio-Path during the 1st quarter valued at approximately $336,000. Vanguard Group Inc. increased its position in Bio-Path by 10.3% during the 2nd quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock valued at $374,000 after purchasing an additional 2,601 shares during the period. Finally, BlackRock Inc. increased its position in Bio-Path by 17.5% during the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after purchasing an additional 6,978 shares during the period. Institutional investors and hedge funds own 11.10% of the company’s stock.

A number of research analysts have recently commented on BPTH shares. ValuEngine raised shares of Bio-Path from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Bio-Path in a report on Friday.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Story: What Factors Can Affect Return on Equity?

Earnings History for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.